Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/2/2024 | $11.00 | Buy | ROTH MKM |
4 - GT Biopharma, Inc. (0000109657) (Issuer)
4 - GT Biopharma, Inc. (0000109657) (Issuer)
4 - GT Biopharma, Inc. (0000109657) (Issuer)
DEF 14A - GT Biopharma, Inc. (0000109657) (Filer)
PRE 14A - GT Biopharma, Inc. (0000109657) (Filer)
8-K - GT Biopharma, Inc. (0000109657) (Filer)
Issued on behalf of GT Biopharma, Inc.GT Biopharma, Inc. (NASDAQ:GTBP) said it has integrated AI-based tools across the discovery and engineering of its tumor-targeting NK cell engagers and multi-domain proteins, efficiency gains the company expects to push multiple new development candidates into pre-IND development in 2027.SAN FRANCISCO, July 6, 2026 /CNW/ -- American News Group News Commentary, Artificial intelligence has become a fixture in biotech marketing, but the more consequential question is where it is actually used: in the slide deck, or at the bench. GT Biopharma, Inc. (NASDAQ:GTBP), a clinical-stage immuno-oncology company, says it is applying AI to the latter, embedding AI-bas
Issued on behalf of GT Biopharma, Inc.GT Biopharma, Inc. (NASDAQ:GTBP) says newly implemented AI-based tools are accelerating its drug discovery and engineering, with multiple new development candidates expected to move into pre-IND development in 2027 and potential indications expanding beyond oncology.USA News Group News CommentaryNEW YORK, June 30, 2026 /CNW/ -- Drug discovery has long been a slow, expensive process of trial and error, and for a small clinical-stage company, every wasted experiment is capital it can scarcely afford. That is the backdrop for a recent update from GT Biopharma, Inc. (NASDAQ:GTBP), a clinical-stage immuno-oncology company built around its proprietary natural
Issued on behalf of GT Biopharma, Inc. Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash them — with the promise of off-the-shelf, lower-toxicity treatments for cancers that have resisted everything else. SAN FRANCISCO, June 12, 2026 (GLOBE NEWSWIRE) -- Equity Insider News Commentary — The last decade of cancer immunotherapy was written largely in the language of T cells. Checkpoint inhibitors unleashed them; CAR-T therapies re-engineered them and produced some of the most dramatic remissions modern medicine has ever recorded. But T-cell therapies also carry hard limits: they can be brutally toxic, they are often manufactured one p
ROTH MKM initiated coverage of GT Biopharma with a rating of Buy and set a new price target of $11.00
HC Wainwright & Co. initiated coverage of GT Biopharma with a rating of Buy and set a new price target of $25.00
B. Riley Securities initiated coverage of GT Biopharma with a rating of Buy and set a new price target of $21.00
Issued on behalf of GT Biopharma, Inc. USA News Group News Commentary VANCOUVER, BC, Dec. 4, 2025 /PRNewswire/ -- Triple-therapy immunotherapy approaches are demonstrating complete leukemia elimination in preclinical models by reprogramming how cancer cells die to trigger powerful immune responses[1], while breakthrough natural killer cell research is revealing new pathways to supercharge the body's innate tumor-fighting capabilities[2]. These developments position GT Biopharma, Inc. (NASDAQ:GTBP), Geron Corporation (NASDAQ:GERN), Kura Oncology, Inc. (NASDAQ:KURA), SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), and TScan Therapeutics, Inc. (NASDAQ:TCRX). The FDA's November approval of the f
SAN FRANCISCO, CALIFORNIA, June 13, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, today announced the appointment of David C. Mun-Gavin to its Board of Directors. "We are very pleased to welcome David to the Board of Directors. David is an experienced senior executive with global connections and a proven track record of success in working with corporate management teams," said Michael Breen, Executive Chairman and Chief Executive Officer of GT Biopharma. "His guidance and perspective will be
SAN FRANCISCO, CALIFORNIA, May 14, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, today announced the appointment of Hilary Kramer to its Board of Directors. Mrs. Kramer will be replacing current board member Bruce Wendel, who is resigning his position. "We are delighted to welcome Hilary to the Board of Directors at this exciting time, and we look forward to leveraging her expertise as we continue to make great clinical progress with our NK engagers," said Michael Breen, Executive Chairman a
Issued on behalf of GT Biopharma, Inc. After more than $1.7 billion in dealmaking and a string of Phase 1 starts in 2026, prostate, pancreatic, and other historically immunotherapy-resistant solid tumors are suddenly among the busiest battlegrounds in oncology — and a new natural killer cell engager just joined the field SAN FRANCISCO, May 14, 2026 (GLOBE NEWSWIRE) -- World Street Intelligence News Commentary — Until very recently, the immuno-oncology revolution had largely passed several of the most lethal solid tumor categories by. Checkpoint inhibitors, which transformed outcomes in melanoma, lung cancer, and renal cell carcinoma, have struggled to deliver meaningful benefit for the m
Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 17, 2025 /PRNewswire/ -- Equity Insider News Commentary – MIT and Harvard scientists recently created engineered CAR-NK cells that hide from the immune system and more effectively destroy cancer, opening doors to off-the-shelf treatments doctors can administer immediately after diagnosis instead of waiting weeks for personalized cell production[1]. Eight new oncology approvals between July and September 2025 demonstrate how cellular immunotherapy platforms are solving manufacturing challenges while expanding from blood cancers into solid tumors, with researchers discovering ways to reprogram immune cell
Believe Urgent Change is Needed at Research Solutions to Address Underperformance, Poor Operational Execution, and Lack of Accountability Highlight that Since Roy Olivier Became Chief Executive Officer, Research Solutions' Share Price Has Declined More than 20% THOUSAND OAKS, Calif., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Peter Derycz, Bristol Investment Fund Ltd. ("Bristol Fund") and certain of Bristol Fund's affiliates (collectively, the "Group"), who collectively beneficially own approximately 20% of Research Solutions, Inc.'s (NASDAQ:RSSS) outstanding shares, today issued an open letter from Mr. Derycz to RSSS shareholders regarding why change is needed at RSSS and the Group's intention t
SC 13G/A - GT Biopharma, Inc. (0000109657) (Subject)
SC 13G/A - GT Biopharma, Inc. (0000109657) (Subject)
SC 13G - GT Biopharma, Inc. (0000109657) (Subject)